Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
366 articles
New compounds targeting the cPLA2 enzyme may reduce Alzheimer's-linked brain inflammation, especially in high-risk APOE4 gene carriers.
Declining Menin in the hypothalamus drives inflammation and aging. Restoring it reversed decline; D-serine amino acid improved cognition in mice.
A completed RCT tests whether 6 months of moderate aerobic exercise protects memory and brain structure in older adults at genetic risk for Alzheimer's.
A 3-month fish hydrolysate supplement significantly improved episodic memory in healthy seniors showing accelerated cognitive decline, with reduced inflammation markers.
A newly identified molecular chain reaction links tau aggregates to neuronal death, revealing ZBP1 as a promising therapeutic target in Alzheimer's disease.
A traditional Chinese herbal formula improves cognition and cerebrovascular health in Alzheimer's mice by activating the LKB1-AMPK-SIRT1 autophagy cascade.
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
Sleep-wake patterns measured by wearables significantly predict dementia risk in 57,000+ older adults, matching the predictive power of genetic testing.
Researchers test a quantile-aggregation approach that may improve how Alzheimer's clinical trials detect treatment effects.
A spatial proteomics platform profiled 700,000+ brain cells, identifying a microglial subset that clusters around amyloid-β plaques in Alzheimer's disease.
A new deep learning model from UCSF predicts Alzheimer's diagnosis and cognitive trajectories from one MRI scan—no expensive multimodal imaging required.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
